The nuclear receptor ESRRA is a crucial regulator of acute kidney injury through inhibition of the lipophagy-ferroptosis axis Authors: Yuanting Yang, Xuying Zhu, Yan Fang, Jialin Li, Xinghua Shao, Shu Li, Haijiao Jin, Chaojun Qi, Zhenyuan Li, Leyi Gu, Shan Mou, Qisheng Lin, Zhaohui Ni Published: 2026 ABSTRACT ABSTRACTAcute kidney injury (AKI) is a clinically significant syndrome characterized by a rapid decline in renal function, affecting over 50% of patients in intensive care units. Ferroptosis, a recently identified form of regulated cell death, is driven by iron-dependent lipid peroxidation and has been implicated in AKI pathogenesis. Emerging evidence suggests that lipophagy – a selective autophagic degradation of lipid droplets – potentiates ferroptosis, though the upstream regulatory mechanisms remain poorly understood. ESRRA (estrogen related receptor, alpha), a key transcriptional regulator of fatty acid metabolism and macroautophagy/autophagy, may play a critical role in this process. In this study, we identified ESRRA as a pivotal transcription factor in proximal tubular epithelial cells using single-cell transcriptomic analysis. To investigate its functional role, we employed wild-type mice and tubular epithelial cell-specific Esrra deficient mice to establish AKI models. Our findings demonstrated that ESRRA exerted a protective effect by modulating the RAB7-dependent lipophagy-ferroptosis axis. Furthermore, integrating chromatin Immunoprecipitation (ChIP)-seq and JASPAR database analyses, we predicted PIK3CA as a direct transcriptional target of ESRRA. Mechanistically, ESRRA bind to a specific promoter region within Pik3ca, enhancing its expression and subsequently activating the AKT-MTOR signaling pathway, which is required for the suppression of RAB7 mediated lipophagy in renal tubular epithelial cells, thereby attenuating AKI progression.Abbreviations: ACSL4: acyl-CoA synthetase long-chain family member 4; AKI: acute kidney injury; AKT/PKB: Akt serine/threonine kinase; ChIP: chromatin Immunoprecipitation; Cis-AKI: cisplatin-induced acute kidney injury; CI-AKI: contrast-induced acute kidney injury; ER: endoplasmic reticulum; ESRRA: estrogen related receptor, alpha; FFAs: free fatty acids; FA-AKI: folic acids-induced acute kidney injury; GPX4: glutathione peroxidase 4; GSH: glutathione; HK-2 cells: human renal proximal tubular epithelial cells; LDs: lipid droplets; LV: lentivirus; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; MTOR: mechanistic target of rapamycin kinase; PPARGC1A/PGC1-α: PPARG coactivator 1 alpha; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PLIN2: perilipin 2; PNPLA2/ATGL: patatin-like phospholipase domain containing 2; PT: proximal tubular epithelial cells; PUFA: polyunsaturated fatty acid; RAB7: RAB7, member RAS oncogene family; ROS: reactive oxygen species; SQSTM1: sequestosome 1. Introduction Acute kidney injury (AKI) is a clinically significant syndrome characterized by a progressive rise in serum creatinine, dysregulation of water-electrolyte and acid-base homeostasis, and oliguria (or non-oliguric renal dysfunction) [1]. According to the multicenter AKI-epidemiology (AKI-EPI) study, AKI affects 10–15% of hospitalized patients, with an incidence exceeding 50% in intensive care units (ICUs) [2,3]. Elevated serum creatinine levels in AKI correlate directly with increased mortality (10–20%), even among non-ICUs patients [4]. Common etiologies include sepsis, nephrotoxic agents (e.g., cisplatin, folic-acid), and contrast-induced injury [3]. Emerging evidence implicates programmed cell death [5], oxidative stress [6], macroautophagy/autophagy dysregulation [7], and lipid metabolism disturbances [8] in AKI pathogenesis. However, the precise molecular mechanisms remain incompletely understood, necessitating further exploration to improve therapeutic strategies. Ferroptosis, a recently identified form of iron-dependent regulated cell death, is distinct from apoptosis and necrosis in its morphological, biochemical, and genetic features, marked by intracellular iron accumulation and lipid peroxidation [9]. Key pathways governing ferroptosis include iron metabolism dysregulation, lipid peroxidation via ACSL4 (acyl-CoA synthetase long-chain family member 4)-mediated polyunsaturated fatty acid (PUFA) activation, and GPX4 (glutathione peroxidase 4) inactivation [10]. Notably, GPX4 utilizes reduced glutathione (GSH) to detoxify lipid peroxides, thereby suppressing ferroptosis. Studies have linked ferroptosis to AKI induced by cisplatin, folic-acid, and sepsis [11–14], yet its upstream regulatory mechanisms remain elusive. Autophagy, a lysosome-dependent degradation process critical for cellular homeostasis [15], was initially considered unrelated to ferroptosis. However, recent findings demonstrate that selective autophagy subtypes – such as lipophagy (lipid droplet degradation), ferritinophagy (iron release), and clockophagy (circadian protein turnover) – promote ferroptosis by increasing free fatty acids (FFAs), labile iron pools, or disrupting clock balance [16]. Lipid droplets (LDs), endoplasmic reticulum (ER)-derived organelles storing triglycerides and cholesterol [17], are degraded via lipophagy, wherein autophagosomes deliver LDs to lysosomes [18]. This process is regulated by RAB7 (RAB7, member RAS oncogene family), a small GTPase essential for lysosomal recruitment to LDs [19]. Mounting evidence indicates that lipophagy drives ferroptosis [16,20,21]. Our prior work first establishes that RAB7-mediated lipophagy exacerbates ferroptosis in renal tubular epithelial cells, contributing to sepsis-induced AKI [22]. Nevertheless, the upstream regulatory mechanisms remain undefined. ESRRA (estrogen related receptor, alpha), an orphan nuclear receptor lacking a known natural ligand, is a key transcriptional regulator of fatty acid metabolism [23]. ESRRA exerts metabolic control via coactivator PPARGC1A/PGC1-α (PPARG coactivator 1 alpha) and is highly expressed in metabolically active tissues, including the kidney [24,25]. Recent studies have established ESRRA as a critical transcriptional regulator of autophagy, demonstrating a fundamental link between this nuclear receptor and autophagic processes [26,27]. In renal pathology, ESRRA mitigates tubular fibrosis by coupling lipid metabolism to epithelial differentiation [28]. However, its role in AKI, particularly in modulating lipophagy-ferroptosis crosstalk, has not been investigated. In this study, we identified ESRRA as a pivotal transcription factor in proximal tubular cells via single-cell RNA sequencing. Using tubular epithelial cells Esrra-knockout mice and multiple AKI models, we demonstrated that ESRRA protected against AKI by suppressing the RAB7-mediated lipophagy-ferroptosis axis. Integrative chromatin Immunoprecipitation (ChIP)-seq and JASPAR database analyses predicted PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) as a direct ESRRA target. Further investigation revealed that ESRRA binds to the PIK3CA promoter, enhances its transcription, and activates the downstream AKT (Akt serine/threonine kinase)-MTOR (mechanistic target of rapamycin kinase) pathway. Based on the canonical inhibitory role of MTOR in autophagy and our concurrent observation of suppressed lipophagy, we propose a working model wherein ESRRA attenuates AKI by activating the PIK3CA-AKT-MTOR axis, which is required for the suppression of lipophagy and ferroptosis. Results Ferroptosis is upregulated in acute kidney injury Our study systematically investigated ferroptosis activation across three well-established AKI models. In the contrast-induced AKI (CI-AKI) model, tail vein injection of iohexol (10 ml/kg) resulted in elevated serum creatinine and blood urea nitrogen levels (Figure 1(A)). Histopathological examination through HE and PAS staining revealed characteristic tubular epithelial cell vacuolization and interstitial inflammation, accompanied by increased renal injury scores (Figure 1(B)), confirming successful model establishment. The folic acid-induced AKI (FA-AKI) model (Figure 1(C)), generated by intraperitoneal injection of folic-acid (250 mg/kg), demonstrated impaired renal function (Figure 1(C)). Histological analysis showed typical tubular dilation and brush border loss (Figure 1(D)), with elevated tubular injury scores (Figure 1(D)). Similarly, cisplatin-induced AKI (Cis-AKI) exhibited renal dysfunction (Fig. S1A-B) along with pathological features including cast formation and epithelial vacuolization (Fig. S1C-D). Figure 1.Enhanced ferroptosis in acute kidney injury. (A) Construction of contrast induced acute kidney injury (CI-AKI). Briefly, the CI-AKI mice were established by unilateral nephrectomy, dehydration, and furosemide (10 ml/kg body weight, injected via the tail vein). For CI-AKI mouse model, the mice were injected with iohexol (10 ml/kg body weight, injected through the tail vein). And the model group mice were injected with saline (10 ml/kg body weight, injected via the tail vein). All mice were sacrificed after 24 h; renal function was evaluated by serum creatinine and bun, n = 5. (B) Representative histology and pathological tubular injury score by he and PAS staining. Scale bar: 20× = 100 μm, 40× = 50 μm. (C) Construction of folic acids induced acute kidney injury (FA-AKI). Briefly, the FA-AKI mice were established by intraperitoneal injection of folic acid (250 mg/kg body weight, dissolved in 0.3 mol/L sodium bicarbonate) or vehicle. All mice were sacrificed after 72 h; renal function was evaluated by serum creatinine and bun, n = 5. (D) Representative histology and pathological tubular injury score by he and PAS staining. Scale bar: 20× = 100 μm, 40× = 50 μm. (E) Differentially expressed genes in bulk-RNA sequencing were showed by volcano plot. Among them, there were 2040 upregulated genes and 2737 downregulated genes in AKI. (F) Heatmap analysis of ferroptosis driver genes/FDGs and ferroptosis inhibitor genes/FIGs was performed using bulk RNA-seq data. (G-H) Immunoblot analysis and quantification of ACSL4 and GPX4 in CI-AKI and FA-AKI mice. (I) Mitochondrial morphology in renal tubular epithelial cells was examined by transmission electron microscopy (TEM). Scale bar: 500 nm, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.The image A showing the construction of contrast-induced acute kidney injury (CI-AKI) in mice, detailing unilateral nephrectomy, dehydration and furosemide administration. Graphs display blood urea nitrogen and serum creatinine levels for control, model and CI-AKI groups. The image B showing histological examination with HE and PAS staining at magnifications of 20X and 40X, comparing control, model and CI-AKI groups, with tubular injury scores. The image C showing folic acid-induced acute kidney injury (FA-AKI) model, detailing folic acid administration and execution timeline. Graphs display blood urea nitrogen and serum creatinine levels for control and FA-AKI groups. The image D showing histological examination with HE and PAS staining at magnifications of 20X and 40X, comparing control and FA-AKI groups, with tubular injury scores. The image E showing a volcano plot of differentially expressed genes in acute kidney injury versus control, highlighting upregulated and downregulated genes. The image F showing heatmap analysis of ferroptosis driver and inhibitor genes using bulk RNA-seq data. The image G showing immunoblot analysis of ACSL4 and GPX4 proteins in CI-AKI mice, with quantification graphs. The image H showing immunoblot analysis of ACSL4 and GPX4 proteins in FA-AKI mice, with quantification graphs. The image I showing transmission electron microscopy images of mitochondrial morphology in renal tubular epithelial cells for control, CI-AKI and FA-AKI groups.Nine panels showing acute kidney injury models, histology, gene expression and protein analysis in mice. Enhanced ferroptosis in acute kidney injury. (A) Construction of contrast induced acute kidney injury (CI-AKI). Briefly, the CI-AKI mice were established by unilateral nephrectomy, dehydration, and furosemide (10 ml/kg body weight, injected via the tail vein). For CI-AKI mouse model, the mice were injected with iohexol (10 ml/kg body weight, injected through the tail vein). And the model group mice were injected with saline (10 ml/kg body weight, injected via the tail vein). All mice were sacrificed after 24 h; renal function was evaluated by serum creatinine and bun, n = 5. (B) Representative histology and pathological tubular injury score by he and PAS staining. Scale bar: 20× = 100 μm, 40× = 50 μm. (C) Construction of folic acids induced acute kidney injury (FA-AKI). Briefly, the FA-AKI mice were established by intraperitoneal injection of folic acid (250 mg/kg body weight, dissolved in 0.3 mol/L sodium bicarbonate) or vehicle. All mice were sacrificed after 72 h; renal function was evaluated by serum creatinine and bun, n = 5. (D) Representative histology and pathological tubular injury score by he and PAS staining. Scale bar: 20× = 100 μm, 40× = 50 μm. (E) Differentially expressed genes in bulk-RNA sequencing were showed by volcano plot. Among them, there were 2040 upregulated genes and 2737 downregulated genes in AKI. (F) Heatmap analysis of ferroptosis driver genes/FDGs and ferroptosis inhibitor genes/FIGs was performed using bulk RNA-seq data. (G-H) Immunoblot analysis and quantification of ACSL4 and GPX4 in CI-AKI and FA-AKI mice. (I) Mitochondrial morphology in renal tubular epithelial cells was examined by transmission electron microscopy (TEM). Scale bar: 500 nm, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Bulk RNA sequencing analysis of AKI kidney tissues identified 2,040 upregulated and 2,737 downregulated genes (Figure 1(E)), with notable upregulation of ferroptosis-driver genes/FDGs and downregulation of ferroptosis-inhibitory genes/FIGs (Figure 1(F)). Western blot analysis consistently showed increased expression of the pro-ferroptotic protein ACSL4 and decreased levels of the anti-ferroptotic protein GPX4 in CI-AKI, FA-AKI and Cis-AKI models (Figure 1(G-H), Figure S1E-G). Electron microscopy revealed hallmark ultrastructural changes of ferroptosis, including mitochondrial swelling and cristae disruption, in both CI-AKI and FA-AKI groups (Figure 1(I)). These findings align with our previous report on sepsis-associated AKI [22], collectively demonstrating ferroptosis activation as a common pathogenic mechanism in diverse forms of acute kidney injury. Iohexol activates ferroptosis in human renal tubular epithelial cells To examine the direct effects of iohexol on renal tubular cells in vitro, we treated human renal proximal tubular epithelial (HK-2) cells with iohexol, using equiosmolar mannitol solution as an osmotic control (Fig. S1H). The CCK-8 assay demonstrated reduced cell viability following iohexol treatment compared to control cells (Fig. S1I). Immunoblot analysis revealed molecular changes characteristic of ferroptosis in iohexol treated cells. We observed increased expression of ACSL4, a key enzyme promoting lipid peroxidation, along with decreased levels of the antioxidant enzyme GPX4 (Fig. S1J-L). The lipid peroxidation probe BODIPY™ 581/591 C11 was used to label the cellular reactive oxygen species (ROS). Iohexol treated cells showed a distinct shift from reduced to oxidized states of lipid ROS (Fig. S1M), confirming enhanced lipid peroxidation. These in vitro findings mirror our observations from animal models, demonstrating that iohexol consistently activates ferroptotic pathways in renal tubular epithelial cells. Enhanced lipophagy activation in acute kidney injury KEGG and GO enrichment analyses revealed significant involvement of lipid metabolism and fatty acid metabolism pathways in AKI progression (Figure 2(A)). To further investigate lipid metabolic changes, we performed LC-MS/MS-based metabolomic profiling (Fig. S2A-D), which demonstrated elevated levels of PUFAs and FFAs in CI-AKI compared to control, suggesting increased lipolytic activity (Figure 2(B) and Figure S2F-G). Given that lipolysis occurs through multiple pathways including both enzymatic hydrolysis and autophagy-mediated degradation (lipophagy), we examined autophagy related gene expression. Heatmap analysis revealed substantial upregulation of autophagy related genes in AKI (Figure 2(C)), and the MAP1LC3B/LC3B (microtubule-associated protein 1 light chain 3 beta) turnover was significantly increased in CI-AKI (Fig. S3C). To further rule out the potential role of lipolysis in promoting ferroptosis, we examined the expression of PNPLA2/ATGL (patatin-like phospholipase domain containing 2), the rate-limiting enzyme of lipolysis. Western blot results showed that PNPLA2 was significantly downregulated in the CI-AKI, FA-AKI, and Cis-AKI groups compared to the ctrl group (Fig. S3E). Similarly, in vitro experiments revealed that iohexol induced downregulation of PNPLA2 protein in HK-2 cells (Fig. S3F). More importantly, treatment with atglistatin, a specific inhibitor of PNPLA2, did not alleviate cell death in our in vitro AKI model (Fig. S3G). This functionally demonstrates that the neutral lipolysis pathway is not the primary driver of the observed phenotype. This observation, combined with our metabolomic and transcriptomic data, led us to hypothesize that lipophagy contributes to ferroptosis in AKI. To test this hypothesis, we analyzed key markers of lipophagy. Immunoblotting demonstrated increased autophagy flux (evidenced by changes in SQSTM1 and LC3-II levels) and elevated expression of RAB7, a critical regulator of autolysosome-lipid droplet docking, in all three AKI models compared to controls (Figure 2(D-E), Figure S3M). Ultrastructural analysis by transmission electron microscopy identified lipid droplets were sequestered by autophagic machinery (lysosome or autolysosome) in both CI-AKI and FA-AKI groups (Figure 2(F)). Immunofluorescence colocalization studies provided additional evidence, showing increased interaction between RAB7, the lipid droplet surface protein PLIN2 (perilipin 2), and the autophagosome marker LC3B in kidney tissues from CI-AKI and FA-AKI models (Figure 2(G)), and the quantitative analysis of colocalization puncta formation as shown in Figure S3H-K. Collectively, these multimodal investigations demonstrate enhanced activation of lipophagy in AKI. Figure 2.Enhanced lipophagy activation in acute kidney injury. (A) KEGG and GO enrichment analyses revealed significant enrichment of differentially expressed genes in pathways related to lipid metabolism and fatty acid metabolism.(B) the distribution of polyunsaturated fatty acids between groups was shown by box plots. (C) Heatmap analysis of autophagy related genes was performed using bulk RNA-seq data. (D-E) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 in CI-AKI and FA-AKI mice. (F) Lipophagosome (lipid droplets engulfed by autophagsome) in renal tubular epithelial cells was observed by TEM. Scale bar: 500 nm. (G) Representative immunofluorescence image of RAB7 (red) with LC3B (green) and PLIN2 (red) with LC3B (green) in CI-AKI and FA-AKI mice kidney tubue. Scale bar: 25 μm, 50 μm. n = 5. (H) Immunoblot analysis and quantification of SQSTM1(B), LC3-II(C) and RAB7(D) in HK-2 cells. (I) Representative immunofluorescence image of RAB7 with LC3B in HK-2 cells. Scale bar: 50 μm. (J) Representative immunofluorescence image of lysosome (red: LysoTracker) and autophagosomes (red: LC3B) with LDs (green: BODIPY 493/503) in HK-2 cells. Scale bar: 50 μm. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.Image A: KEGG pathway analysis showing gene percentages and pathways. Image B: Box plots of lipid metabolites' relative abundance across groups. Image C: Heatmap of autophagy-related genes with gene names and samples. Image D: Immunoblot analysis of SQSTM1, LC3-I, LC3-II, RAB7 and ACTB with expression graphs. Image E: Immunoblot analysis in FA-AKI for SQSTM1, LC3-I, LC3-II, RAB7 and ACTB, with expression graphs. Image F: TEM images of lipid droplets in Ctrl, CI-AKI and FA-AKI groups. Image G: Immunofluorescence of RAB7, LC3B and PLIN2 in Ctrl, Model, CI-AKI and FA-AKI groups with enlarged views. Image H: Immunoblot analysis in Mannitol and Iohexol groups for SQSTM1, LC3-I, LC3-II, RAB7 and ACTB, with expression graphs. Image I: Immunofluorescence of RAB7 and LC3B in Ctrl, Mannitol and Iohexol groups. Image J: Immunofluorescence of LysoTracker and LC3B with BODIPY in Ctrl, Mannitol and Iohexol groups.Composite image with KEGG pathway, gene expression, immunoblot, TEM and immunofluorescence analyses in AKI models. Enhanced lipophagy activation in acute kidney injury. (A) KEGG and GO enrichment analyses revealed significant enrichment of differentially expressed genes in pathways related to lipid metabolism and fatty acid metabolism.(B) the distribution of polyunsaturated fatty acids between groups was shown by box plots. (C) Heatmap analysis of autophagy related genes was performed using bulk RNA-seq data. (D-E) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 in CI-AKI and FA-AKI mice. (F) Lipophagosome (lipid droplets engulfed by autophagsome) in renal tubular epithelial cells was observed by TEM. Scale bar: 500 nm. (G) Representative immunofluorescence image of RAB7 (red) with LC3B (green) and PLIN2 (red) with LC3B (green) in CI-AKI and FA-AKI mice kidney tubue. Scale bar: 25 μm, 50 μm. n = 5. (H) Immunoblot analysis and quantification of SQSTM1(B), LC3-II(C) and RAB7(D) in HK-2 cells. (I) Representative immunofluorescence image of RAB7 with LC3B in HK-2 cells. Scale bar: 50 μm. (J) Representative immunofluorescence image of lysosome (red: LysoTracker) and autophagosomes (red: LC3B) with LDs (green: BODIPY 493/503) in HK-2 cells. Scale bar: 50 μm. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Iohexol activates lipophagy in human renal tubular epithelial cells In vitro investigations demonstrated that iohexol treatment significantly enhanced lipophagy in HK-2 cells. Immunoblot analysis revealed characteristic changes in autophagy markers, including decreased SQSTM1 levels and increased LC3-II conversion, accompanied by elevated expression of RAB7, a critical regulator of lipophagy (Figure 2(H)). Supporting these findings, immunofluorescence microscopy demonstrated increased colocalization between LC3B-positive autophagosomes and RAB7 in iohexol-treated cells compared to controls (Figure 2(I)). The colocalization of neutral lipid droplets (BODIPY™ 493/503) with autophagosomes (LC3B) and lysosomes (LysoTracker™) was observed by confocal microscopy, and the results showed that the colocalization of lipid droplets with autophagosomes and lysosomes increased after iohexol treatment (Figure 2(J)). The above data suggest that iohexol promotes the activation of lipophagy in vitro, which is consistent with the results of animal model findings. Single-cell transcriptomic profiling identifies ESRRA downregulation in renal tubular epithelial cells during acute kidney injury We performed single-cell RNA sequencing using the 10x Genomics platform to comprehensively characterize cellular heterogeneity in kidney tissues from 3 control mice and 3 AKI mice. After stringent quality control, our analysis included a total of 53,242 high-quality cells, consisting of 25,812 cells from healthy controls and 27,430 cells from AKI mice. Unsupervised first clustering analysis identified 15 distinct cell populations based on established kidney cell markers (Table S2). The renal intrinsic cells comprised 23,127 proximal tubular epithelial cells (PT), 4,697 loop of Henle cells (LOH), 1,850 distal tubular epithelial cells (DT), 1,047 collecting duct principal cells (CD-PC), 288 collecting duct intercalated cells (CD-IC), 8,740 endothelial cells (Endo), 194 fibroblasts, and 380 smooth muscle cells (SMCs). The immune cell populations included 6,693 macrophages, 1,408 neutrophils, 259 monocytes, 861 dendritic cells (DCs), 939 B lymphocytes, 2,280 T lymphocytes, and 484 natural killer cells (NK cells) (Figure 3(A-B)). Focusing on PT cells, we further classified them into healthy (Ctrl) and injured (CI-AKI) subpopulations based on the expression of established kidney injury markers Havcr1 and Lcn2 for subsequent analysis (Figure 3(C-D)). Figure 3.Single-cell transcriptomic profiling identifies ESRRA downregulation in renal tubular epithelial cells during acute kidney injury. (A) Uniform manifold approximation and projection (UMAP) indicating a total of 53,242 cells color-coded by different cell types. pt, proximal tubular epithelial cells; LOH, loop of henle cells; dt, distal tubular epithelial cells; CD-PC, collecting duct principal cells; CD-IC, collecting duct intercalated cells; Endo, endothelial cells; fibro, fibroblasts; SMC, smooth muscle cells; macro, macrophages; Neu, neutrophils; Mono, monocytes; DCs, B-cells, B lymphocytes; T-cells, T lymphocytes; NK, natural killer cells. (B) Dot plot showing the expression of marker genes in different cell types. (C) UMAP indicating subclustered pt cells color-coded by healthy and injured pt cells. (D) Respective UMAP indicating the marker genes of injured pt cells. (E) Volcano plot displaying differentially expressed transcription factors in pt cells. (F) Dot plot showing the expression of Esrra in different cell types. (G) Violin plots showing Esrra expression in pt cells between Ctrl and CI-AKI groups. (H) Violin plot showing the expression levels of Esrra in renal tubular cells (pt, LOH, DCT and CD-PC). (I) Immunoblot analysis and quantification of ESRRA in CI-AKI and S-AKI mice. (J) Immunoblot analysis and quantification of ESRRA in FA-AKI and Cis-AKI mice. (K) Dot plot showing the expression levels of ferroptosis-related genes (Acsl4, Gpx4 and Hmox1) and lipophagy-related genes (Rab7, Map1lc3a and Map1lc3b). (L) Violin plot showing the expression levels of ferroptosis-related genes (Acsl4, Gpx4 and Hmox1) and lipophagy-related genes (Rab7, Map1lc3a and Map1lc3b). n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.The image A showing a UMAP scatter plot of 53,242 renal cells. The x-axis label is UMAP underscore 1 (unitless embedding) and y-axis label is UMAP underscore 2 (unitless embedding). Fifteen distinct clusters are labeled: proximal tubular epithelial cells (23127), loop of henle cells (4697), distal tubular epithelial cells (1850), collecting duct principal cells (1047), collecting duct intercalated cells (288), endothelial cells (8740), fibroblasts (194), smooth muscle cells (380), macrophages (6693), neutrophils (1408), monocytes (259), dendritic cells (861), B lymphocytes (939), T lymphocytes (2280) and natural killer cells (484). The image B showing a dot plot. The x-axis lists marker genes; the y-axis lists cell types. Dot size encodes expression percent and dot shading encodes average expression level. The image C showing a UMAP scatter plot of subclustered proximal tubular epithelial cells. Axes are unitless UMAP embeddings ranging from minus 10 to 10. Two groups are distinguished: healthy proximal tubular epithelial cells (Ctrl) and injured proximal tubular epithelial cells (CI-AKI). The image D showing two UMAP feature plots titled Havcr1 and Lcn2, both with unitless UMAP embedding axes, marking injured proximal tubular epithelial cells. The image E showing a volcano scatter plot titled proximal tubular epithelial cells. The x-axis is labeled delta percentage difference (unitless); the y-axis is labeled log2 foldchange (unitless). Dashed lines indicate cutoff thresholds. Down-regulated genes total 387; up-regulated genes total 232. Notable labeled up-regulated genes include Klf6, Tsc22d1, Atf4, Litaf, Fosl1 and Tgif1. The image F showing a dot plot of Esrra expression across all 15 cell types. Dot size encodes expression percent (0 to 30) and shading encodes average expression (minus 1 to 1). Proximal tubular epithelial cells show the highest Esrra expression. The image G showing a violin plot titled Esrra in proximal tubular epithelial cells. The y-axis is labeled expression (normalized, unitless). CI-AKI group shows markedly lower Esrra expression compared to Ctrl. The image H showing four violin plots for Esrra across proximal tubular epithelial cells, loop of henle cells, distal tubular epithelial cells and collecting duct principal cells. All four cell types show significantly lower Esrra expression in CI-AKI versus Ctrl (p less than 0.0001). The image I showing immunoblot bands for ESRRA at 50 kilodaltons and ACTB at 42 kilodaltons across Ctrl, Model, CI-AKI, S-AKI groups. Bar charts show relative expression of ESRRA over ACTB. CI-AKI and S-AKI groups show significantly reduced ESRRA protein levels compared to Ctrl (p less than 0.0001). The image J showing immunoblot bands for ESRRA at 50 kilodaltons and ACTB at 42 kilodaltons across Ctrl, FA-AKI and Cis-AKI groups. Bar charts confirm significantly reduced ESRRA in FA-AKI and Cis-AKI versus Ctrl (p less than 0.0001). The image K showing a dot plot in proximal tubular epithelial cells comparing CI-AKI and Ctrl. The y-axis lists ferroptosis-related genes Acsl4, Gpx4, Hmox1 and lipophagy-related genes Rab7, Map1lc3a, Map1lc3b. Dot size encodes expression percent (0 to 70); shading encodes average expression (0.0 to 0.4). The image L showing violin plots for the same six genes in proximal tubular epithelial cells. The y-axis is labeled expression (normalized, unitless); x-axis groups are CI-AKI and Ctrl. Acsl4, Hmox1 and Map1lc3a show visibly elevated expression in CI-AKI versus Ctrl.Esrra downregulated in kidney cells in 4 injury models vs. controls. Single-cell transcriptomic profiling identifies ESRRA downregulation in renal tubular epithelial cells during acute kidney injury. (A) Uniform manifold approximation and projection (UMAP) indicating a total of 53,242 cells color-coded by different cell types. pt, proximal tubular epithelial cells; LOH, loop of henle cells; dt, distal tubular epithelial cells; CD-PC, collecting duct principal cells; CD-IC, collecting duct intercalated cells; Endo, endothelial cells; fibro, fibroblasts; SMC, smooth muscle cells; macro, macrophages; Neu, neutrophils; Mono, monocytes; DCs, B-cells, B lymphocytes; T-cells, T lymphocytes; NK, natural killer cells. (B) Dot plot showing the expression of marker genes in different cell types. (C) UMAP indicating subclustered pt cells color-coded by healthy and injured pt cells. (D) Respective UMAP indicating the marker genes of injured pt cells. (E) Volcano plot displaying differentially expressed transcription factors in pt cells. (F) Dot plot showing the expression of Esrra in different cell types. (G) Violin plots showing Esrra expression in pt cells between Ctrl and CI-AKI groups. (H) Violin plot showing the expression levels of Esrra in renal tubular cells (pt, LOH, DCT and CD-PC). (I) Immunoblot analysis and quantification of ESRRA in CI-AKI and S-AKI mice. (J) Immunoblot analysis and quantification of ESRRA in FA-AKI and Cis-AKI mice. (K) Dot plot showing the expression levels of ferroptosis-related genes (Acsl4, Gpx4 and Hmox1) and lipophagy-related genes (Rab7, Map1lc3a and Map1lc3b). (L) Violin plot showing the expression levels of ferroptosis-related genes (Acsl4, Gpx4 and Hmox1) and lipophagy-related genes (Rab7, Map1lc3a and Map1lc3b). n = 5, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Through integrated analysis of single-cell transcriptomic data and the TRRUST Version2 transcription factor database (TRRUST-Transcriptional Regulatory Relationships Unraveled by Sentence-based Text mining), and previous research on transcription factors known to regulate lipid metabolism and autophagy, we identified ESRRA as a potential transcriptional regulator involved in the lipophagy-ferroptosis axis during AKI pathogenesis (Figure 3(E)). Comparative analysis of PT cells from healthy and injured kidneys demonstrated that Esrra, a nuclear receptor known to regulate lipid metabolism and autophagy [23,26,27], was abundantly expressed in healthy tubular cells but significantly downregulated in injured epithelial cells across multiple tubular segments, including PT, LOH, DCT, and CD-PC (Figure 3(F-H)). This downregulation was specific to renal tubular epithelial populations and not observed in glomerular or immune cells (Fig. S4A). The reduction of ESRRA expression in AKI was consistently observed at both mRNA and protein levels. Quantitative analysis confirmed decreased Esrra mRNA levels in CI-AKI (Fig. S4B), and immunoblotting revealed corresponding reductions in ESRRA protein expression across AKI models, including contrast-induced, folic acid-induced, cisplatin-induced, and sepsis-associated AKI (Figure 3(I-J)). Concurrent with ESRRA downregulation, we observed molecular signatures indicative of activated ferroptosis and lipophagy pathways in injured tubular cells. Single-cell transcriptional profiling revealed increased expression of ferroptosis-driver genes (Acsl4 and Hmox1) alongside decreased expression of the ferroptosis-inhibitory gene (Gpx4). Furthermore, elevated expression of lipophagy-related genes (Rab7 and Map1lc3b) was detected in AKI (Figure 3(K-L)). Overall, these data confirmed the decrease of ESRRA in PT cells in AKI mice, which is a potential transcription factor regulating lipophagy and ferroptosis. The nuclear receptor ESRRA regulates iohexol induced lipophagy and ferroptosis ESRRA, a key transcriptional regulator of fatty acid metabolism and autophagy, was investigated for its role in iohexol-induced renal tubular injury. We established stable ESRRA-overexpressing HK-2 cell lines through lentiviral transduction (Figure 4(A)), with immunoblot analysis confirming successful overexpression (Figure 4(B)). Functional assessment revealed that ESRRA overexpression attenuated iohexol-induced cytotoxicity, as evidenced by improved cell viability compared to control cells (Figure 4(C)). At the molecular level, ESRRA overexpression demonstrated protective effects against iohexol-induced cellular changes. Immunoblot analysis showed that elevated ESRRA expression suppressed both ferroptosis and lipophagy activated by iohexol exposure (Figure 4(D-E)). To further validate these findings, we employed XCT790, a specific ESRRA inverse agonist, to pharmacologically inhibit ESRRA activity in HK-2 cells (Figure 4(F)). Immunoblotting confirmed effective suppression of ESRRA signaling following XCT790 treatment (Figure 4(G)). Functional consequences of ESRRA inhibition were examined through multiple approaches. The CCK-8 assay demonstrated that ESRRA blockade exacerbated iohexol-induced cell death (Figure 4(H)). Molecular analysis revealed enhanced activation of both ferroptosis and lipophagy upon ESRRA inhibition (Figure 4(I-J)). Using the lipid peroxidation probe BODIPY™ 581/591 C11, we observed that ESRRA inhibition intensified iohexol-induced lipid ROS production (Figure 4(K)). Immunofluorescence microscopy further showed increased colocalization of LC3B-labeled autophagosomes with RAB7, a key lipophagy regulator, following ESRRA suppression (Figure 4(L)). These data suggested that overexpression or inhibition of ESRRA regulates iohexol-induced ferroptosis and lipophagy. Figure 4.The nuclear receptor ESRRA regulates iohexol induced lipophagy and ferroptosis. (A) Lentiviral transduction efficiency in human renal tubular epithelial cells: multiplicity of infection (MOI = 50) and transduction reagent (reagent P) selection (selection based on >50% fluorescence intensity and effective minimal MOI). (B) Immunoblot analysis and quantification of ESRRA identifying the overexpression efficiency of ESRRA. (C) CCK8-assay revealing the cell viability after ESRRA overexpression. (D) Immunoblot analysis and quantification of ACSL4, GPX4 after ESRRA overexpression. (E) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 after ESRRA overexpression. (F) Schematic illustration of XCT790 pretreatment: HK-2 cells were pretreated with 10 μM XCT790 for 24 h, followed by iohexol stimulation for 6 h before cell collection. (G) Immunoblot analysis and quantification of ESRRA identifying the inhibition efficiency of ESRRA by XCT790 pretreatment. (H) CCK8-assay revealing the cell viability after ESRRA inhibition. (I) Immunoblot analysis and quantification of ACSL4, GPX4 after ESRRA inhibition by XCT790. (J) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 after ESRRA inhibition by XCT790. (K) BODIPYTM 581/591 C11 probe showed lipid peroxidation (red: non-oxidized lipids, green: oxidized lipids) after ESRRA inhibition by XCT790. (L) Representative immunofluorescence image of RAB7 with LC3B in HK-2 cells after ESRRA inhibition by XCT790. Scale bar: 10X: 100 μm; 20X: 50 μm. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.A twelve-panel composite scientific figure examining ESRRA regulation of iohexol-induced ferroptosis and lipophagy in HK-2 cells. Panel A shows fluorescence images of lentiviral transduction at three multiplicities of infection across three reagent conditions, with multiplicity of infection 50 and reagent P selected. Panel B shows immunoblots confirming ESRRA overexpression versus vector control, with ACTB as loading reference. Panel C presents a bar graph with iohexol treatment on the x-axis and cell viability percentage on the y-axis, showing ESRRA overexpression maintains higher viability versus vector under iohexol, marked with asterisks indicating p less than 0.05 and p less than 0.001. Panel D shows immunoblots and quantification bar graphs for ACSL4 at 69 kilodaltons and GPX4 at 17 kilodaltons, with ESRRA overexpression reducing iohexol-induced changes, marked p less than 0.01 and p less than 0.0001. Panel E shows SQSTM1, LC3-II and RAB7 immunoblots and bar graphs, with ESRRA overexpression attenuating autophagy marker alterations. Panel F is a schematic of XCT790 pretreatment followed by iohexol stimulation. Panel G confirms ESRRA suppression by XCT790. Panel H shows cell viability bar graph with XCT790 worsening iohexol-induced death. Panels I and J show ACSL4, GPX4, SQSTM1, LC3-II and RAB7 levels increased with XCT790 plus iohexol. Panel K shows fluorescence images of non-oxidized and oxidized lipids with a merged channel, indicating intensified lipid peroxidation after XCT790. Panel L shows RAB7 and LC3B immunofluorescence with merged channel demonstrating increased colocalization after ESRRA inhibition.ESRRA overexpression boosts HK-2 cell viability, reducing ferroptosis and lipophagy. The nuclear receptor ESRRA regulates iohexol induced lipophagy and ferroptosis. (A) Lentiviral transduction efficiency in human renal tubular epithelial cells: multiplicity of infection (MOI = 50) and transduction reagent (reagent P) selection (selection based on >50% fluorescence intensity and effective minimal MOI). (B) Immunoblot analysis and quantification of ESRRA identifying the overexpression efficiency of ESRRA. (C) CCK8-assay revealing the cell viability after ESRRA overexpression. (D) Immunoblot analysis and quantification of ACSL4, GPX4 after ESRRA overexpression. (E) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 after ESRRA overexpression. (F) Schematic illustration of XCT790 pretreatment: HK-2 cells were pretreated with 10 μM XCT790 for 24 h, followed by iohexol stimulation for 6 h before cell collection. (G) Immunoblot analysis and quantification of ESRRA identifying the inhibition efficiency of ESRRA by XCT790 pretreatment. (H) CCK8-assay revealing the cell viability after ESRRA inhibition. (I) Immunoblot analysis and quantification of ACSL4, GPX4 after ESRRA inhibition by XCT790. (J) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 after ESRRA inhibition by XCT790. (K) BODIPYTM 581/591 C11 probe showed lipid peroxidation (red: non-oxidized lipids, green: oxidized lipids) after ESRRA inhibition by XCT790. (L) Representative immunofluorescence image of RAB7 with LC3B in HK-2 cells after ESRRA inhibition by XCT790. Scale bar: 10X: 100 μm; 20X: 50 μm. n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Renal tubular epithelial cell-specific ESRRA deficiency exacerbates acute kidney injury Single-cell transcriptomic analysis revealed abundant expression of the nuclear receptor ESRRA in healthy renal tubular epithelial cells (Fig. S4A). To investigate the functional consequences of ESRRA loss in tubular epithelial cells, we generated tubule-specific esrra knockout mice by crossing Esrraflox/flox mice with Cdh16-Cre transgenic mice, enabling targeted deletion of the Esrra gene on chromosome 19 specifically in renal tubular cells (Figure 5(A)). Through this breeding strategy, we obtained two experimental groups: Esrra-WT (Esrraflox/flox Cdh16-Cre−) control mice and esrra-cKO (esrraflox/flox Cdh16-Cre+) knockout mice (Figure 5(B)). Genotyping by PCR confirmed successful recombination (Figure 5(C)), and immunoblot analysis verified efficient ESRRA protein depletion in tubular epithelial cells (Figure 5(D)). Functional characterization demonstrated that tubular-specific esrra deletion exacerbated renal injury across multiple AKI models (Figure 5(E,H)). Following contrast media administration, esrra-cKO mice showed more severe renal dysfunction compared to controls, as evidenced by elevated serum creatinine and blood urea nitrogen levels (Figure 5(F)). Histopathological examination revealed aggravated tubular damage in knockout mice, including prominent epithelial cell vacuolization and interstitial inflammatory infiltration (Figure 5(G)). This detrimental effect of ESRRA deficiency was consistently observed in other AKI models. In folic acid-induced AKI, esrra-cKO mice exhibited worse renal function impairment (Figure 5(I)) and more severe tubular dilation (Figure 5(J)). Similarly, cisplatin-treated esrra-cKO mice showed exacerbated renal dysfunction and increased tubular cast formation compared to Esrra-WT mice (Fig. S8A-C). These findings collectively demonstrated that conditional deficiency of ESRRA specifically in renal tubular epithelial cells aggravated both functional and structural kidney damage across diverse AKI etiologies. The consistent phenotypic outcomes observed in CI-AKI, FA-AKI and Cis-AKI models underscore the critical protective role of tubular ESRRA in maintaining renal homeostasis during acute kidney injury. Figure 5.Renal tubular epithelial cell-specific esrra deficiency exacerbates acute kidney injury. (A) Schematic illustration of esrra-specific knockout in renal tubular epithelia cells by Loxp-Cre system. (B) Schematic illustration of genetic crossing protocol for esrra-specific knockout in renal tubular epithelia cells. (C) Genotype identification through tail DNA analysis. (D) Immunoblot analysis and quantification of ESRRA identifying the specific knockout efficiency of ESRRA. (E) Schematic diagram of contrast media-induced AKI model in renal tubule-specific esrra knockout mice. (F) Renal function was evaluated by serum creatinine and bun in Esrra-WT and esrra-cKO mice after contrast agent administration, n = 5. (G) Representative histology he and PAS staining and tubular injury score in Esrra-WT and esrra-cKO mice after contrast agent administration, n = 5, scale bar: 20x = 100 μm, 40x = 50 μm. (H) Schematic diagram of folic acid-induced AKI model in renal tubule-specific Esrra knockout mice. (I) Renal function was evaluated by serum creatinine and bun in Esrra-WT and esrra-cKO mice after folic acids treatment, n = 5. (J) Representative histology he and PAS staining and pathological tubular injury score in Esrra-WT and esrra-cKO mice after folic acids treatment, n = 5, scale bar: 20x = 100 μm, 40x = 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.A scientific figure with panels A-J. Image A: Esrra gene on chromosome 19 with loxP sites for Cre knockout. Image B: Genetic crossing for Esrra-WT and esrra-cKO mice using Cdh16-Cre. Image C: Genotype via tail DNA analysis showing Esrra flox/flox and Cdh16Cre bands. Image D: Immunoblot of ESRRA at 50 kDa and ACTB at 42 kDa in Esrra-WT and esrra-cKO. Image E: CI-AKI model timeline with nephrectomy, dehydration, furosemide and iohexol. Image F: Serum creatinine and BUN plots for Ctrl and CI-AKI groups, esrra-cKO shows higher values (****). Image G: HE and PAS histology at 20x and 40x for Esrra-WT CI-AKI and esrra-cKO CI-AKI, higher tubular injury in esrra-cKO (****). Image H: FA-AKI model timeline. Image I: Serum creatinine and BUN plots for FA-AKI, esrra-cKO elevated. Image J: HE and PAS at 20x and 40x for FA-AKI, higher tubular injury in esrra-cKO (****).ESRRA knockout: schematics, bar plots, blots, histology in AKI mouse models. Renal tubular epithelial cell-specific esrra deficiency exacerbates acute kidney injury. (A) Schematic illustration of esrra-specific knockout in renal tubular epithelia cells by Loxp-Cre system. (B) Schematic illustration of genetic crossing protocol for esrra-specific knockout in renal tubular epithelia cells. (C) Genotype identification through tail DNA analysis. (D) Immunoblot analysis and quantification of ESRRA identifying the specific knockout efficiency of ESRRA. (E) Schematic diagram of contrast media-induced AKI model in renal tubule-specific esrra knockout mice. (F) Renal function was evaluated by serum creatinine and bun in Esrra-WT and esrra-cKO mice after contrast agent administration, n = 5. (G) Representative histology he and PAS staining and tubular injury score in Esrra-WT and esrra-cKO mice after contrast agent administration, n = 5, scale bar: 20x = 100 μm, 40x = 50 μm. (H) Schematic diagram of folic acid-induced AKI model in renal tubule-specific Esrra knockout mice. (I) Renal function was evaluated by serum creatinine and bun in Esrra-WT and esrra-cKO mice after folic acids treatment, n = 5. (J) Representative histology he and PAS staining and pathological tubular injury score in Esrra-WT and esrra-cKO mice after folic acids treatment, n = 5, scale bar: 20x = 100 μm, 40x = 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ESRRA deficiency in renal tubular epithelial cells exacerbates ferroptosis and lipophagy activation in acute kidney injury To elucidate the molecular mechanisms by which ESRRA deficiency aggravates renal injury, we performed comprehensive analyses of ferroptosis and lipophagy pathways in contrast-induced and folic acid-induced AKI model. Immunoblot examination of kidney tissues from tubule specific esrra knockout mice demonstrated markedly enhanced ferroptosis activation following contrast agent exposure, as shown by characteristic changes in key ferroptosis regulatory proteins (Figure 6(A-B)). Concurrent evaluation of lipophagy activity revealed that ESRRA deficiency significantly amplified contrast-induced lipophagic responses. Western blot analysis of kidney lysates showed elevated expression of both the lipophagy mediator RAB7 and the autophagosomal protein SQSTM1 in esrra-cKO mice compared to Esrra-WT mice (Figure 6(C-D)). Immunofluorescence co-localization and relative quantitative analysis demonstrated increased interaction between RAB7, the lipid droplet marker PLIN2, and autophagosomal structures in renal tubules of esrra-cKO mice following contrast administration (Figure 6(E-F) and Figure S8D-E). These analyses consistently demonstrated that conditional deficiency of ESRRA in renal tubular epithelial cells potentiates both ferroptosis and lipophagy activation in contrast-induced acute kidney injury. Figure 6.Esrra deficiency in renal tubular epithelial cells exacerbates ferroptosis and lipophagy activation in acute kidney injury. (A-B) Immunoblot analysis (a) and quantification (b) of ACSL4 and GPX4 in Esrra-WT and esrra-cKO mice after contrast agent administration. (C-D) Immunoblot analysis (C) and quantification (d) of SQSTM1 and LC3-II in Esrra-WT and esrra-cKO mice after contrast agent administration.(E-F) Representative immunofluorescence image of PLIN2 (green) with LC3B (red) and RAB7 (green) with LC3B (red) in kidney tubule. Scale bar: 50 μm. n = 5. (G-H) Immunoblot analysis (G) and quantification (H) of ACSL4 and GPX4 in Esrra-WT and esrra-cKO mice after folic acid treatment. (I-J) Immunoblot analysis (i) and quantification (j) of SQSTM1 and LC3-II in Esrra-WT and esrra-cKO mice after folic acid treatment. (K-L) Representative immunofluorescence image of PLIN2 (green) with LC3B (red) and RAB7 (green) with LC3B (red) in kidney tubule. Scale bar: 50 μm. n = 5; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.Images A and G show immunoblot analysis of ACSL4, GPX4 and ACTB in Esrra-WT and esrra-cKO mice after contrast agent and folic acid treatments. Images B and H quantify ACSL4 and GPX4 levels, highlighting significant differences with asterisks. Images C and I display immunoblot analysis of SQSTM1, RAB7 and ACTB post-treatment. Images D and J quantify SQSTM1 and LC3-II levels, noting significant differences. Images E and K present immunofluorescence of PLIN2 with LC3B in kidney tubules, including merged and enlarged views. Images F and L show immunofluorescence of LC3B with RAB7 in kidney tubules, also with merged and enlarged views.Panels of immunoblot and immunofluorescence images on ESRRA deficiency in kidney injury. Esrra deficiency in renal tubular epithelial cells exacerbates ferroptosis and lipophagy activation in acute kidney injury. (A-B) Immunoblot analysis (a) and quantification (b) of ACSL4 and GPX4 in Esrra-WT and esrra-cKO mice after contrast agent administration. (C-D) Immunoblot analysis (C) and quantification (d) of SQSTM1 and LC3-II in Esrra-WT and esrra-cKO mice after contrast agent administration.(E-F) Representative immunofluorescence image of PLIN2 (green) with LC3B (red) and RAB7 (green) with LC3B (red) in kidney tubule. Scale bar: 50 μm. n = 5. (G-H) Immunoblot analysis (G) and quantification (H) of ACSL4 and GPX4 in Esrra-WT and esrra-cKO mice after folic acid treatment. (I-J) Immunoblot analysis (i) and quantification (j) of SQSTM1 and LC3-II in Esrra-WT and esrra-cKO mice after folic acid treatment. (K-L) Representative immunofluorescence image of PLIN2 (green) with LC3B (red) and RAB7 (green) with LC3B (red) in kidney tubule. Scale bar: 50 μm. n = 5; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ESRRA deficiency in renal tubular epithelial cells aggravated ferroptosis and lipophagy. This was also verified in the folic acid induced AKI model, as shown by immunoblot for ferroptosis regulatory proteins (ACSL4 and GPX4) (Figure 6(G-H)), lipophagy proteins (SQSTM1 and RAB7) (Figure 6(I-J)) and immunofluorescence co-localization between RAB7, PLIN2 and LC3B (Figure 6(K-L) and Figure S8F-G). These results demonstrated that the pro-ferroptotic and lipophagy-enhancing effects of ESRRA deficiency were not limited to contrast-induced injury but represent a generalized response to different forms of nephrotoxic stress. The consistent pattern of pathway activation observed in both FA-AKI and CI-AKI models underscores the fundamental role of ESRRA in maintaining lipid homeostasis and cellular survival in renal tubular epithelium. The nuclear receptor ESRRA suppresses lipophagy-ferroptosis through the transcriptional regulation of Pik3ca and subsequent AKT-MTOR pathway activation To elucidate the molecular mechanism by which ESRRA regulates the lipophagy-ferroptosis axis in renal tubular cells, we performed comprehensive genomic and functional analyses. Using the Cistrome Data Browser (http://cistrome.org/db/#/), we analyzed ESRRA ChIP-seq data and identified a prominent binding peak on chromosome 3 (179146125–179148125), corresponding to the transcription start site of the Pik3ca gene (Figure 7(A)). This bioinformatic prediction was experimentally validated through ChIP assays. ChIP-qPCR and ChIP-PCR analyses demonstrated significant enrichment of Pik3ca promoter sequences in ESRRA immunoprecipitates compared to control IgG precipitates (Figure 7(B-C)), confirming direct binding of ESRRA to the Pik3ca promoter region. We next investigated the functional consequences of this transcriptional regulation on downstream signaling pathways. Immunoblot analysis revealed that iohexol treatment reduced phosphorylation levels of both AKT and MTOR (Figure 7(D)). Importantly, genetic manipulation of ESRRA expression directly influenced this pathway. ESRRA overexpression enhanced AKT and MTOR phosphorylation (Figure 7(E)), while pharmacological inhibition of ESRRA with XCT790 suppressed their activation (Figure 7(F)). To establish the causal relationship between ESRRA-mediated PIK3CA-AKT-MTOR signaling and lipophagy-ferroptosis regulation, we employed pharmacological modulators of AKT and MTOR. Pretreatment with the AKT or MTOR inhibitor MK-2206 or rapamycin abolished the protective effects of ESRRA overexpression against iohexol-induced ferroptosis (Figure 7(G) and Figure S8H) and lipophagy (Figure 7(H) and Figure S8I). Conversely, MTOR activation with MHY1485 mitigated the exacerbating effects of ESRRA blockade on these processes (Figure 7(I-J)). Figure 7.The nuclear receptor ESRRA suppresses lipophagy-ferroptosis through transcriptional regulation of PIK3CA and subsequent AKT-MTOR pathway activation. (A) Circos plot showing genome-wide distribution of ESRRA ChIP-seq peaks (http://cistrome.org/db/#/, CistromeDB: 39355). (B) ChIP-qPCR identifying ESRRA binding to PIK3CA promoter, data shown as percent input (%). (C) ChIP-PCR identifying ESRRA binding to PIK3CA promoter. (D) Immunoblot analysis and quantification of p-AKT and p-MTOR in HK-2 cells. (E) Immunoblot analysis and quantification of p-AKT and p-MTOR after ESRRA overexpression. (F) Immunoblot analysis and quantification of p-AKT and p-MTOR after ESRRA inhibition by XCT790 pretreatment. (G) Immunoblot analysis and quantification of ACSL4 and GPX4 after rapamycin treatment upon ESRRA overexpression. (H) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 after rapamycin treatment upon ESRRA overexpression. (I-J) Immunoblot analysis and quantification of ACSL4, GPX4, SQSTM1, LC3-II and RAB7 after MHY1485 treatment upon ESRRA inhibition. n = 3. (K) Immunoblot analysis and quantification of p-MTOR in Esrra-WT and esrra-cKO mice. n = 5. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.A shows a Circos plot with ESRRA ChIP-seq peaks and the Pik3ca gene promoter region. B presents a Chip-qPCR graph showing ESRRA binding to the promoter. C displays a gel image of the Pik3ca promoter. D shows immunoblot analysis of p-AKT and p-MTOR in different treatments, with graphs of relative expression. E presents immunoblot and graphs for p-AKT and p-MTOR with ESRRA overexpression. F shows immunoblot and graphs for p-AKT and p-MTOR with XCT790 treatment. G displays immunoblot and graphs for ACSL4 and GPX4 with rapamycin treatment. H shows immunoblot and graphs for SQSTM1, LC3-II and RAB7 with rapamycin treatment. I presents immunoblot for ACSL4 and GPX4 with XCT790 and MHY1485 treatment. K shows immunoblot and graph for p-MTOR in Esrra-WT and Esrra-cKO mice.ESRRA's role in AKT-MTOR via ChIP-seq, qPCR, immunoblot analyses under varied conditions shown in 9 panels. The nuclear receptor ESRRA suppresses lipophagy-ferroptosis through transcriptional regulation of PIK3CA and subsequent AKT-MTOR pathway activation. (A) Circos plot showing genome-wide distribution of ESRRA ChIP-seq peaks (http://cistrome.org/db/#/, CistromeDB: 39355). (B) ChIP-qPCR identifying ESRRA binding to PIK3CA promoter, data shown as percent input (%). (C) ChIP-PCR identifying ESRRA binding to PIK3CA promoter. (D) Immunoblot analysis and quantification of p-AKT and p-MTOR in HK-2 cells. (E) Immunoblot analysis and quantification of p-AKT and p-MTOR after ESRRA overexpression. (F) Immunoblot analysis and quantification of p-AKT and p-MTOR after ESRRA inhibition by XCT790 pretreatment. (G) Immunoblot analysis and quantification of ACSL4 and GPX4 after rapamycin treatment upon ESRRA overexpression. (H) Immunoblot analysis and quantification of SQSTM1, LC3-II and RAB7 after rapamycin treatment upon ESRRA overexpression. (I-J) Immunoblot analysis and quantification of ACSL4, GPX4, SQSTM1, LC3-II and RAB7 after MHY1485 treatment upon ESRRA inhibition. n = 3. (K) Immunoblot analysis and quantification of p-MTOR in Esrra-WT and esrra-cKO mice. n = 5. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Complementary in vivo studies demonstrated that tubule-specific esrra knockout mice exhibited reduced MTOR phosphorylation in CI-AKI compared to wild-type mice (Figure 7(K)). These collective findings support a working model whereby ESRRA binding to the PIK3CA promoter enhances its transcription, which activates the AKT-MTOR pathway and is associated with the suppression of lipophagy-ferroptosis in renal tubular cells. The nuclear receptor ESRRA directly binds to a specific sequence in the Pik3ca promoter region Following our demonstration of ESRRA-mediated transcriptional regulation of Pik3ca, we sought to precisely identify the binding site responsible for this interaction. Using the JASPAR 2024 database, we predicted that ESRRA binds to the CCAAGGTCT sequence within the Pik3ca promoter region (Figure 8(A,B)). A schematic representation illustrates this transcriptional regulation mechanism, showing ESRRA binding to this specific sequence at chromosome 3 position 179146125-179148125 to regulate Pik3ca transcription (Figure 8(C)). To experimentally validate this binding site, we constructed dual-luciferase reporter plasmids containing either the wild-type (pGL3-Basic-H_PIK3CA promoter WT) or mutant (pGL3-Basic-H_PIK3CA promoter MT) versions of the predicted binding sequence (Figure 8(D)). Luciferase assays in ESRRA overexpressing and control cell lines demonstrated significantly enhanced fluorescence intensity at the wild-type binding site in ESRRA overexpressing cells compared to controls (Figure 8(E)). Importantly, mutation of the CCAAGGTCT sequence substantially reduced reporter activity in ESRRA overexpressing cells (Figure 8(F)), confirming sequence specificity. Functional validation of this binding interaction showed that cells transfected with the mutant binding site plasmid exhibited significantly reduced MTOR phosphorylation compared to those receiving the wild-type plasmid (Figure 8(G)). These results collectively demonstrate that ESRRA regulates Pik3ca transcription through direct binding to the CCAAGGTCT sequence in the Pik3ca promoter region, establishing a molecular link between ESRRA DNA-binding activity and downstream AKT-MTOR pathway activation. Figure 8.The nuclear receptor ESRRA directly binds to a specific sequence in the PIK3CA promoter region. (A) Sequence logo representing nucleotide frequencies in the identified motif. Total stack height denotes position conservation (measured in bits), while individual letter sizes reflect relative base frequencies (a: green, t: red, C: blue, G: orange). (B) Position frequency matrix (PFM) representing the distribution of four nucleotide bases at each position. (C) Schematic illustration showing ESRRA transcriptionally regulating PIK3CA gene. (D) the construction ofdual-luciferase reporter plasmids containing either the wild-type (pGL3-Basic-H_PIK3CA promoter wt) or mutant (pGL3-Basic-H_PIK3CA promoter MT) versions of the predicted binding sequence. (E) Schematic illustration of dual-luciferase reporter assay. (F) Relative luciferase activity of promoter wt and promoter MT in lentivirus NC and lentivirus ESRRA cells. (G) Immunoblot analysis of p-MTOR after promoter wt and promoter MT plasmids transduction. n = 3; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.The infographic illustrates the binding of ESRRA to the PIK3CA promoter. A shows a sequence logo with nucleotide frequencies. B provides a frequency matrix for ESRRA. C highlights the transcription start site of PIK3CA on chromosome 3, region 377-385, with the sequence CCAAGGTCT. D depicts plasmid construction for wild-type and mutant PIK3CA promoter sequences. E explains the dual-luciferase reporter assay with lentivirus NC and ESRRA, showing transcription activation. F presents relative luciferase activity, indicating higher activity in ESRRA overexpressing cells with the wild-type promoter. G displays immunoblot analysis of P-MTOR, MTOR and ACTB after transduction with wild-type and mutant promoters, showing reduced MTOR phosphorylation with the mutant. The sequence for the wild-type and mutant promoters is provided at the bottom.Infographic on ESRRA binding to PIK3CA promoter, showing sequence, assays and luciferase activity. The nuclear receptor ESRRA directly binds to a specific sequence in the PIK3CA promoter region. (A) Sequence logo representing nucleotide frequencies in the identified motif. Total stack height denotes position conservation (measured in bits), while individual letter sizes reflect relative base frequencies (a: green, t: red, C: blue, G: orange). (B) Position frequency matrix (PFM) representing the distribution of four nucleotide bases at each position. (C) Schematic illustration showing ESRRA transcriptionally regulating PIK3CA gene. (D) the construction ofdual-luciferase reporter plasmids containing either the wild-type (pGL3-Basic-H_PIK3CA promoter wt) or mutant (pGL3-Basic-H_PIK3CA promoter MT) versions of the predicted binding sequence. (E) Schematic illustration of dual-luciferase reporter assay. (F) Relative luciferase activity of promoter wt and promoter MT in lentivirus NC and lentivirus ESRRA cells. (G) Immunoblot analysis of p-MTOR after promoter wt and promoter MT plasmids transduction. n = 3; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Discussion This study elucidates key molecular mechanisms in AKI. We reveal the RAB7‑mediated lipophagy‑ferroptosis axis as a critical driver of tubular injury through integrated multi‑omics and functional analyses. Furthermore, we identify ESRRA as a key transcriptional regulator in tubular epithelial cells by regulating lipophagy‑ferroptosis in vivo and in vitro AKI models. Mechanistically, ESRRA activates the PIK3CA-AKT-MTOR pathway via direct promoter binding, an event functionally linked to the suppression of lipophagy‑ferroptosis. These findings establish ESRRA as a central regulator coordinating protective metabolic and autophagic responses in AKI (Figure 9). Figure 9.Schematic illustration of the nuclear receptor ESRRA protecting acute kidney injury through inhibition of lipophagy-ferroptosis axis. In healthy kidneys, highly expressed ESRRA maintains the balance between lipid metabolism and autophagy. However, in kidneys with acute kidney injury (AKI), ESRRA is significantly depleted, leading to reduced transcriptional activation of the PIK3CA gene by ESRRA and subsequent inhibition of the downstream AKT-MTOR pathway, which exacerbates the activation of lipophagy. Excessive lipophagy results in intracellular FFAs accumulation, further promoting lipid peroxidation and ferroptosis, thereby contributing to the pathogenesis of AKI.The image illustrates the role of ESRRA in kidney health and injury. On the left, a healthy tubular cell shows ESRRA maintaining autophagy and lipid metabolism. On the right, a ferroptotic tubular cell shows reduced ESRRA leading to disordered autophagy and lipid metabolism. ESRRA binds to ERRE, activating the Pik3ca gene, producing Pik3ca RNA. This activates the PI3K-AKT-MTOR pathway, inhibiting excessive lipophagy. RAB7 is involved in lipophagy, leading to free fatty acids accumulation, lipid peroxidation and ferroptosis. ACSL4 and GPX4 are associated with ferroptosis. The diagram highlights the transition from healthy to injured kidney cells due to reduced ESRRA expression.ESRRA protects kidneys by regulating lipophagy-ferroptosis and lipid metabolism. Schematic illustration of the nuclear receptor ESRRA protecting acute kidney injury through inhibition of lipophagy-ferroptosis axis. In healthy kidneys, highly expressed ESRRA maintains the balance between lipid metabolism and autophagy. However, in kidneys with acute kidney injury (AKI), ESRRA is significantly depleted, leading to reduced transcriptional activation of the PIK3CA gene by ESRRA and subsequent inhibition of the downstream AKT-MTOR pathway, which exacerbates the activation of lipophagy. Excessive lipophagy results in intracellular FFAs accumulation, further promoting lipid peroxidation and ferroptosis, thereby contributing to the pathogenesis of AKI. The relationship between lipid metabolism disorders and AKI has gained increasing attention, emerging as a critical factor in AKI pathogenesis [29]. While renal tubular epithelial cells primarily rely on fatty acid oxidation for energy production, accumulating evidence indicates that excessive PUFAs and FFAs contribute to renal damage through lipotoxicity [30–32]. Our LC-MS/MS metabolomic profiling corroborated these findings, revealing significant accumulation of PUFAs and FFAs in kidney tissues during AKI (Figure 2(B) and Figure S2F-G). These observations suggest that comprehensive PUFAs and FFAs profiling may represent promising diagnostic and prognostic biomarkers for AKI, warranting further investigation. Fatty acid-induced cellular toxicity operates through multiple mechanisms, including mitochondrial dysfunction, ER stress, and lipid peroxidation. For example, oleic acid and palmitic acid treatment caused mitochondrial fissions in renal tubular epithelial cells, resulting in the destruction of fatty acid β oxidation site, which doubled the lipid accumulation [30]. And ectopic lipid deposition (ELD) resulted in kidney injury by elevated ER stress [33]. Notably, excessive fatty acids can be converted into lipid peroxides through the action of ACSL4 and LPCAT3 (lysophosphatidylcholine acyltransferase 3), triggering ferroptosis in ischemic-reperfusion (I/R) injury [34]. Our findings align with and extend previous reports by demonstrating excessive accumulation of FFAs-induced ferroptosis involvement across diverse AKI models, including cisplatin-induced, contrast-induced, folic acid-induced, and sepsis-associated AKI. Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation [9], involves multiple regulatory pathways including iron metabolism, lipid peroxidation, and GPX4 deficiency [10]. In renal pathology, ferroptosis has gained increasing attention as a mediator of AKI. Notably, ferroptosis but not necroptosis has been implicated in folic acid-induced AKI [11]. In addition, the inhibition of histone deacetylase 3 alleviated renal tubular cells ferroptosis in AKI-CKD transition via preserving GPX4 [35]. Last research reported that the inhibition of PAFAH2 (platelet-activating factor acetylhydrolase 2) augmented synchronized ferroptosis and exacerbated I/R-induced AKI [36]. Novel study has revealed that estrogen receptors confer protection against acute kidney injury by suppressing ferroptosis, which elucidates the underlying mechanism for the lower susceptibility of females to this condition [37]. Our findings align with these reports, demonstrating lipid peroxidation and ferroptosis activation across multiple AKI models including contrast-induced, folic acid-induced, cisplatin-induced, and sepsis-induced AKI [22], thereby substantially expanding the evidence for ferroptosis involvement in diverse AKI etiologies. While autophagy represents a fundamental cellular degradation system [38,39], its relationship with ferroptosis has evolved from being considered unrelated to the current understanding that specific selective autophagy forms (lipophagy, ferritinophagy, and clockophagy) promote ferroptosis [40,41] through increased intracellular free fatty acids [21,42], free iron [43,44], and circadian clock protein degradation [45,46]. Lipophagy, a specialized form of lipid catabolism, exhibits dual roles in cellular homeostasis by regulating lipid storage, energy metabolism, and FFAs levels [47]. Lipophagy deficiency leads to intracellular lipid toxicity and impaired fatty acid metabolism, promoting cell death [48,49], while excessive lipophagy activation results in FFAs accumulation that drives lipid peroxidation and oxidative stress [21]. Our previous work first established the activation and regulatory role of lipophagy in ferroptosis during septic AKI [22]. The current study significantly extends these findings by systematically validating lipophagy’s pathogenic role across three classical AKI models and pioneering the investigation of lipid metabolism-autophagy crosstalk in AKI. However, the precise regulatory mechanisms remain elusive, highlighting the urgent need for further research to enable targeted therapeutic intervention of the lipophagy-ferroptosis axis. ESRRA, a key transcriptional regulator of fatty acid metabolism and mitochondrial biogenesis [23], requires the coactivator PPARGC1A/PGC1-α for its transcriptional activity due to the absence of natural ligands [24,50]. Highly expressed in metabolically active tissues including kidneys [25], ESRRA has recently been shown to ameliorate colonic inflammation through autophagy activation and microbiota regulation [26,27], and regulating translation of lysosome and autolysosome proteins during steatohepatitis [51], suggesting its broader role in autophagic regulation. Additionally, ESRRA promotes osteogenesis via lipid metabolic regulation [52], underscoring its systemic protective functions in autophagy and lipid homeostasis. In renal pathology, ESRRA protects against renal fibrosis by coordinating lipid metabolism with tubular epithelial differentiation [28]. Recent advances demonstrate that tubular-specific ESRRA overexpression or stabilization attenuates diabetic nephropathy progression [53,54]. While these studies establish ESRRA’s renoprotective role in chronic kidney disease, our work provides the first evidence for its protective function in AKI, suggesting that ESRRA modulation may represent a novel therapeutic strategy to maintain tubular lipid homeostasis and mitigate AKI progression. The PI3Kα isoform, encoded by PIK3CA, serves as a critical regulator of cellular proliferation, survival, and metabolism [55]. Our ChIP-seq analysis identified PIK3CA as an ESRRA transcriptional target, with subsequent validation of the downstream AKT-MTOR pathway’s involvement in lipophagy regulation. JASPAR database predictions further pinpointed the specific binding site, confirming that ESRRA binds to the PIK3CA promoter to activate AKT-MTOR signaling. While our inhibitor studies establish the AKT-MTOR pathway as a functional upstream suppressor of lipophagy-ferroptosis, the mechanistic interface between MTOR complex and RAB7 or its regulators remains to be elucidated. Elucidating this precise point of crosstalk will be a valuable extension of the regulatory framework outlined here. In summary, this study identifies ESRRA as an important transcriptional protector in AKI. Our research shows that ESRRA works by transcriptionally activating the PIK3CA-AKT-MTOR pathway, which correlates with the suppression of RAB7 mediated lipophagy and ferroptosis. These findings together suggest a protective mechanism that helps attenuate renal injury during AKI. Materials and methods Animals and ethics approval All animal experiments were conducted in accordance with the ARRIVE guidelines 2.0 and were approved by the Animal Care Committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University. Esrraflox/flox (Shanghai Model Organisms Center, NM-CKO-00039) and Cdh16-Cre mice were purchased from the Shanghai Model Organisms Center. Specific knockout of Esrra in renal tubular epithelial —esrra-cKO mice were generated by crossing Esrraflox/flox mice with Cdh16-Cre mice via Cre-LoxP system (Figure 4(B)). After two generations of hybridization, esrra-cKO (esrraflox/flox Cdh16-Cre+) mice and Esrra-WT (Esrraflox/flox Cdh16-Cre−) mice were obtained for subsequent experiments. And the genotypes were confirmed by PCR using mouse tails, and the primer pairs listed in Table S1. Mice were housed under 12 h light-12 h darkness cycles, and the controlled temperature (22°C-24°C) and the controlled humidity (50%-65%). Contrast media induced acute kidney injury (CI-AKI), folic acid induced acute kidney injury (FA-AKI) and cisplatin induced acute kidney injury (Cis-AKI) In the wild-type animal experiments, all animal experiments were conducted using C57BL/6 male mice (8 weeks, 23 g-25 g) and randomly assigned to different experimental groups, with 5 mice per group. A total of 35 male C57BL/6 mice were used in the wild-type animal experiments. In the esrra-specific knockout mice animal experiments, 8-week-old male littermate esrra-cKO and Esrra-WT mice were randomly assigned to different experimental groups, with 5 mice per group. A total of 60 male mice were used in the specific knockout animal studies. The CI-AKI mice were established as are summarized belowdescribed in previous studies. Briefly, the CI-AKI mice were established by unilateral nephrectomy, dehydration, and 10 mg/mL furosemide (Sigma-Aldrich, F4381) in mice treatment (10 ml/kg body weight, injected via the tail vein). To establish the CI-AKI mouse model, the mice were injected through the tail vein with iohexol (GE Healthcare, Omnipaque 350), 10 ml/kg body weight. And the model control group mice were injected via the tail vein with saline, 10 ml/kg body weight. All mice were sacrificed after 24 h, and serum and kidney tissue were collected for subsequent experiments. The FA-AKI mice were established by intraperitoneal injection of 0.3 mol/L folic acid (MedChemExpress, HY-16637) at a dose of 250 mg/kg body weight, which was dissolved in sodium bicarbonate. The mice were euthanized 72 h later. The serum and kidney tissue were collected. The Cis-AKI mice were induced by intraperitoneal injection of cisplatin (Sigma Aldrich, 232120) at a dose of 20 mg/kg body weight, and were euthanized 72 h later, and serum and kidney samples were collected. Cells, antibodies and reagents Human renal proximal tubular cell line (HK-2 cells) was purchased from American Type Culture Collection (ATCC®, CRL-2190). And we obtained the iohexol from GE Healthcare (Omnipaque 350), mannitol (M9546) from Sigma-Aldrich; Folic acid (HY-16637), atglistatin (HY-15859), XCT790 (HY-10426), MK-2206 (HY-108232), rapamycin (HY-10219) and MHY1485 (HY-B0795) from MedChemExpress; Cisplatin (232120) and sodium bicarbonate (144–55-8) from Sigma-Aldrich. We obtained antibodies targeting ACSL4 (ab155282), GPX4 (ab125066) from Abcam; ESRRA (13826), LC3B (2775), RAB7 (9367), phospho-AKT (4060), AKT (9272), phospho-MTOR (5536) and MTOR (2983) from Cell Signaling Technology; PNPLA2/ATGL (55190–1-AP), SQSTM1 (18420–1-AP) and ACTB/Beta Actin (66009–1-Ig) from Proteintech (Table 1); Secondary antibodies for immunoblotting from Beyotime; LysoTracker™ (L12492), BODIPY™ 493/503 (D3922), BODIPY™ 581/591 C11 (D3861) from Thermo Fisher Scientific. We obtained fluorescence secondary antibodies from Abcam: Donkey anti-rabbit IgG (Alexa Fluor® 555, ab150074; Alexa Fluor® 488, ab150073), donkey anti-mouse IgG (Alexa Fluor® 488, ab150105; Alexa Fluor® 555, ab150110).Table 1.List of primary antibodies.Primary antibodiesSourceProviderCatalogApplicationACSL4RabbitAbcamab155282WB (1:3000)GPX4RabbitAbcamab125066WB (1:5000)SQSTM1RabbitProteintech18420–1-APWB (1:1000)LC3BMouseCST2775WB (1:1000); IF (1:200)RAB7RabbitCST9367WB (1:1000); IF (1:200)ESRRARabbitCSST13826WB (1:1000)p-AKTRabbitCST4060WB (1:1000)AKTRabbitCST9272WB (1:1000)p-MTORRabbitCST5536WB (1:1000)MTORRabbitCST2983WB (1:1000)ACTBMouseProteintech66009–1-IgWB (1:5000) Table 1.List of primary antibodies.Primary antibodiesSourceProviderCatalogApplicationACSL4RabbitAbcamab155282WB (1:3000)GPX4RabbitAbcamab125066WB (1:5000)SQSTM1RabbitProteintech18420–1-APWB (1:1000)LC3BMouseCST2775WB (1:1000); IF (1:200)RAB7RabbitCST9367WB (1:1000); IF (1:200)ESRRARabbitCSST13826WB (1:1000)p-AKTRabbitCST4060WB (1:1000)AKTRabbitCST9272WB (1:1000)p-MTORRabbitCST5536WB (1:1000)MTORRabbitCST2983WB (1:1000)ACTBMouseProteintech66009–1-IgWB (1:5000) List of primary antibodies. Preparation of single-cell suspension of kidney tissue samples Freshly collected kidney tissue from mice with a scalpel (or surgical scissors). Under sterile conditions, wash 2 times with pre-chilled RPMI 1640 (Gibco, Thermo Fisher Scientific, 12,633,020) + 0.04% BSA (Sigma Aldrich, B2064) medium. Use surgical scissors to thoroughly chop the tissue into small pieces of about 0.5 mm3 and put them in a freshly prepared enzymatic hydrolyzate (0.2% Collagenase II, Gibco, 17,101,015 and 0.2% trypsin, Gibco, 15,090,046). Enzymatic digestion was carried out in a 37°C incubator for 30–60 min, and mixed by inversion every 5–10 min. The digested cell suspension was filtered 1–2 times with a 40 μm cell strainer (BD Falcon, 352,340) at 4°C and centrifuged at 300 g for 5 min. After the pellet was resuspended with an appropriate amount of medium, an equal volume of red blood cell lysis solution (Miltenyi Biotec GmbH, 130–094-183) was added, mixed and allowed to stand at 4°C for 10 min, 300 g of cell suspension was centrifuged for 5 min, and the supernatant was discarded. The pellet was washed 1 time with medium, centrifuged at 300 g for 5 min, the supernatant was discarded, the cell pellet was resuspended with 100 μl medium, and the cell concentration and viability were calculated by LUNA-FL™ dual fluorescence cell counter (Logos Biosystems, UNA-FX7™). Detailed instruments, reagent brands, and catalog numbers used in the preparation of single-cell suspensions (Table 2) are summarized below:Table 2.Detailed instruments, reagent brands, and catalog numbers used in the preparation of single-cell suspensions.Experimental procedureReagent/consumable/instrumentBrandCat.NoDissociation of mouse kidney tissueTrypsinGibco15090046Collagenase, Type IGibco17018029Collagenase, Type IIGibco17101015Collagenase, Type IVGibco17104019DMEMGibco11995065Enzyme, Bacillus licheniformissigmaP5380Dead cell removal40-μm strainerFalcon352340Red blood cell lysisMACS130–094-183Debris removal solutionMACS130–109-398Dead cell removal kitMACS130–090-101Magnetic activated cell sortingPTPRC/CD45 Micro Beads, mouseMACS130–052-301Cell counterLUNA-FL™ Dual fluorescence cell counterLogos BiosystemsLuna-FL Table 2.Detailed instruments, reagent brands, and catalog numbers used in the preparation of single-cell suspensions.Experimental procedureReagent/consumable/instrumentBrandCat.NoDissociation of mouse kidney tissueTrypsinGibco15090046Collagenase, Type IGibco17018029Collagenase, Type IIGibco17101015Collagenase, Type IVGibco17104019DMEMGibco11995065Enzyme, Bacillus licheniformissigmaP5380Dead cell removal40-μm strainerFalcon352340Red blood cell lysisMACS130–094-183Debris removal solutionMACS130–109-398Dead cell removal kitMACS130–090-101Magnetic activated cell sortingPTPRC/CD45 Micro Beads, mouseMACS130–052-301Cell counterLUNA-FL™ Dual fluorescence cell counterLogos BiosystemsLuna-FL Detailed instruments, reagent brands, and catalog numbers used in the preparation of single-cell suspensions. Dead cell removal Dead cell removal was performed according to the dead cell removal kit (Miltenyi Biotec GmbH, 130–090-101) operating instructions. Briefly, add 100 μl of magnetic beads to the cell suspension, pipette and mix well, incubate at room temperature for 15 min and then pass the column, the eluted cell suspension is centrifuged at 4°C, 300 g for 5 min and washed twice, then resuspended with 50–100 μl medium, and LUNA-FL™ dual fluorescence cell counter counted. Single-cell RNA sequencing and library construction Fresh single-cell suspension was adjusted to 700–1200 cells/μl and prepared according to the 10x Genomics Chromium next GEM single-cell 3ʹ reagent kits v3.1 (10x Genomics, 1,000,268) operating instructions. Briefly, the experimental procedure included: Gel beads-in-emulsions (GEM) generation and barcoding, cDNA extraction and enrichment, library and post library construction quality control. The constructed libraries were sequenced using the Illumina Nova 6000 PE150 platform. Single-cell RNA-sequencing data quality control and processing The FASTQ files were processed and aligned to mm10 mouse reference genome using Cell Ranger software (version 7.0.1) from 10x Genomics, with unique molecular identifier (UMI) counts summarized for each barcode. The UMI count matrix was then analyzed using Seurat (version 4.0.0) R package. To remove low-quality cells and likely multiplet captures, a set of criteria was conducted: cells were filtered by (1) gene numbers (gene numbers < 200), (2) UMI (UMI count < 1000), (3) log10GenesPerUMI (log10GenesPerUMI < 0.7), (4) percentage of mitochondrial RNA UMIs (proportion of UMIs mapped to mitochondrial genes > 10%) and (5) percentage of hemoglobin RNA UMIs (proportion of UMIs mapped to hemoglobin genes > 5%). Subsequently, the DoubletFinder package (version 2.0.3) was used to identify potential doublets. To obtain the normalized gene expression data, library size normalization was processed using the NormalizeData function. Specifically, the global-scaling normalization method “lognormalize” normalized the gene expression measurements for each cell by the total expression, multiplied by a scaling factor 10,000 by default, and log-transformed the results. Top 2000 highly variable genes (HVGs) were calculated using the Seurat function FindVariableGenes (mean.function = FastExpMean, dispersion.function = FastLogVMR). Principal-component analysis (PCA) was performed to reduce the dimensionality with RunPCA function. Graph-based clustering was performed to cluster cells according to their gene expression profile with the FindClusters function. Cells were visualized using a 2-dimensional uniform manifold approximation and projection (UMAP) algorithm with the RunUMAP function. The FindAllMarkers function (test.use = presto) was used to identify marker genes of each cluster. Differentially expressed genes (DEGs) were selected using the function FindMarkers (test.use = presto). p value < 0.05 and |log2foldchange| >0.58 was set as the threshold for significantly differential expression. GO enrichment and KEGG pathway enrichment analysis of DEGs were respectively performed using R (version 4.0.3) based on the hypergeometric distribution. The sequencing and bioinformatics analysis were provided by OE Biotech Co, Ltd. (Shanghai, China). Liquid chromatography-mass spectrometry (LC-MS/MS) metabolomics sample preparation Approximately 30 mg of kidney tissue sample (Ctrl: CI-AKI = 4:9) was weighed and transferred into a 1.5 ml EP tube. Two small steel beads and 400 μL of a methanol-water solution (V:V = 4:1, containing L-2-chlorophenylalanine at 4 μg/ml) were added to the tube. The tube was pre-cooled in a −40°C freezer for 2 min and then homogenized in a grinding mill for 2 min at 60 Hz. After homogenization, the sample was subjected to ultrasonic extraction in an ice-water bath for 10 min, followed by incubation in a −40°C freezer for 30 min. Subsequently, the sample was centrifuged at 4°C and 1200 rpm for 10 min. A 300 μL aliquot of the resulting supernatant was transferred to an LC-MS vial and evaporated to dryness. After evaporation, 300 μL of a methanol-water solution (V:V = 1:4) was added to the vial for reconstitution. The mixture was vortexed for 30 s, sonicated in an ice-water bath for 3 min, and then stored at −40°C for 2 h. The reconstituted extract was then centrifuged again at 4°C and 1200 rpm for 10 min. A 150 μL aliquot of the supernatant was collected, filtered through a 0.22 μm organic phase pinhole filter, and transferred to a fresh LC vial. The final sample was stored at −80°C for subsequent LC-MS analysis. The quality control (QC) sample was prepared by combining equal volumes of extract from all individual samples. Liquid chromatography-mass spectrometry analysis The bioinformatics analysis was provided by OE Biotech Co, Ltd. (Shanghai, China). The analytical instrument used in this experiment was a liquid chromatography-mass spectrometry system consisting of an ACQUITY UPLC I-Class Plus ultra-performance liquid chromatograph coupled with a Q-Exactive Plus high-resolution mass spectrometer, equipped with a heated electrospray ionization (ESI) source (Thermo Fisher Scientific, USA). This system was used to analyze metabolic profiles in both ESI positive and ESI negative ion modes. An ACQUITY UPLC HSS T3 column (1.8 μm, 2.1 × 100 mm) was used for both positive and negative modes. The gradient elution system consisted of (A) water (containing 0.1% formic acid, v/v) and (B) acetonitrile (containing 0.1% formic acid, v/v), using the following gradient program: 0.01 min, 5% B; 2 min, 5% B; 4 min, 30% B; 8 min, 50% B; 10 min, 80% B; 14 min, 100% B; 15 min, 100% B; 15.1 min, 5% B; and 16 min, 5% B. The flow rate was 0.35 ml/min, and the column temperature was maintained at 45°C. All samples were kept at 10°C during the analysis. The mass range was set from 100 m/z to 1200 m/z. The full MS scan resolution was 70,000, and the MS/MS scan resolution was 17,500, with collision energies of 10, 20, and 40 eV, respectively. The mass spectrometer parameters were set as follows: spray voltage, 3800 V (+) and 3200 V (−); sheath gas flow rate, 35 arbitrary units; auxiliary gas flow rate, 8 arbitrary units; capillary temperature, 320°C; auxiliary gas heater temperature, 350°C; and S-lens RF level, 50. Raw data preprocessing and metabolite identification The LC-MS raw data were processed using Progenesis QI V2.3 (Nonlinear Dynamics, Newcastle, UK) for baseline filtering, peak identification, integration, retention time correction, peak alignment, and normalization. The primary parameters were set as follows: 5 ppm precursor tolerance, 10 ppm product tolerance, and a 5% product ion threshold. Compounds were identified by matching precise mass-to-charge ratios (m/z), secondary fragments, and isotope distributions against several databases, including The Human Metabolome Database (HMDB), LipidMaps (V2.3), Metlin, and a custom-built database. The extracted data were then subjected to further processing: any peaks with missing values (ion intensity = 0) in over 50% of the samples within a group were removed. Zero values were replaced by half of the minimum value, and the data were filtered based on the qualitative results of the compounds. Additionally, compounds with a database matching score below 36 (out of a total score of 80) were deemed inaccurate and removed. Finally, the positive and negative ion data were combined into a single data matrix. Data normalization and statistical analysis The data matrix was imported into the R software package for principal component analysis (PCA) to visualize the overall distribution among samples and assess the stability of the entire analytical process. Orthogonal partial least squares-discriminant analysis (OPLS-DA) and partial least squares-discriminant analysis (PLS-DA) were employed to distinguish metabolite differences between groups. To prevent overfitting, a 7-fold cross-validation and a 200-response permutation test (RPT) were used to evaluate the quality of the models. The variable importance in projection (VIP) values obtained from the OPLS-DA model were used to rank the overall contribution of each variable to the group discrimination. A two-tailed Student’s t-test was further applied to verify the significance of the metabolite differences between groups. Differential metabolites were selected based on a VIP value greater than 1.0 and a p-value less than 0.05. The key software tools used for metabolomics (Table 3) are summarized below:Table 3.The key software tools used for metabolomics.Analysis stepSoftware/toolRaw Data ProcessingProgenesis QI V2.3Metabolite DatabasesHMDB, METLINPCA/OPLS-DAR scriptsDifferential MetabolitesStudent’s t-test(VIP > 1.0 and p < 0.05) Table 3.The key software tools used for metabolomics.Analysis stepSoftware/toolRaw Data ProcessingProgenesis QI V2.3Metabolite DatabasesHMDB, METLINPCA/OPLS-DAR scriptsDifferential MetabolitesStudent’s t-test(VIP > 1.0 and p < 0.05) The key software tools used for metabolomics. RNA isolation and library preparation Total RNA was extracted from the renal cortex of control and CI-AKI mice by using the TRIzol reagent (Invitrogen, 15596026CN) according to the manufacturer’s protocol. RNA purity and quantification were evaluated using the NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Then the libraries were constructed using VAHTS universal v6 RNA-seq library prep kit (Vazyme, NR606-01/02) according to the manufacturer’s instructions. The transcriptome sequencing and analysis were conducted by OE Biotech Co., Ltd. (Shanghai, China). RNA sequencing and differentially expressed genes analysis The libraries were sequenced on an IIumina Novaseq 6000 platform and 150 bp paired-end reads were generated. About 23 million raw reads for each sample were generated. Raw reads of fastq format were firstly processed using fastp1 and the low- quality reads were removed to obtain the clean reads. Then about 21 clean reads for each sample were retained for subsequent analyses. The clean reads were mapped to the reference genome using HISAT22. FPKM3 of each gene was calculated and the read counts of each gene were obtained by HTSeq-count4. PCA analysis were performed using R (v 3.2.0) to evaluate the biological duplication of samples. Differential expression analysis was performed using the DESeq25. Q value < 0.05 and foldchange > 2 or foldchange < 0.5 was set as the threshold for significantly differential expression gene (DEGs). Hierarchical cluster analysis of DEGs was performed using R (v 3.2.0) to demonstrate the expression pattern of genes in different groups and samples. The radar map of top 30 genes was plotted to show the expression of up-regulated or down-regulated DEGs using R packet ggradar. Based on the hypergeometric distribution, GO, KEGG pathway enrichment analysis of DEGs were performed to screen the significant enriched term using R (v 3.2.0), respectively. The key software tools used for RNA sequencing (Table 4) are summarized below:Table 4.The key software tools used for RNA sequencing.Analysis stepSoftware/toolSequencing Data Quality ControlfastpSequence AlignmentHISAT2Gene QuantificationHTSeq-countDifferential Expression AnalysisDESeq2 (q < 0.05 and |log2FC|>1)Enrichment AnalysisHypergeometric distribution, R (v 3.2.0) Table 4.The key software tools used for RNA sequencing.Analysis stepSoftware/toolSequencing Data Quality ControlfastpSequence AlignmentHISAT2Gene QuantificationHTSeq-countDifferential Expression AnalysisDESeq2 (q < 0.05 and |log2FC|>1)Enrichment AnalysisHypergeometric distribution, R (v 3.2.0) The key software tools used for RNA sequencing. Lentiviral vector construction and packaging The construction of lentiviral vectors included tool vectors enzymatic digestion target gene fragments acquisition, exchange of PCR products and vectors, and colony PCR identification and sequencing. Briefly, linearized vectors were obtained by restriction enzyme digestion. PCR amplification to prepare the gene fragment of interest. The reaction system was prepared with the linearized vector and the target gene amplification product, and the recombination reaction was carried out to realize the in vitro circularization of the linearized vector and the target gene fragment. The recombinant products were directly transformed, monoclones were picked from the plate for PCR identification, and positive clones were sequenced and the results were analyzed. The correct cloned culture solution was expanded and extracted to obtain a high-purity plasmid for downstream virus packaging. Plasmid extraction was performed with the AmMag Quatro Plasmid Purification Kit-24 prep kit (Genscript, L00882-24). The qualified plasmid was extracted for transfection of HEK293T cells, and the supernatant of the transfected HEK293T cells was collected. Concentrated lentivirus was obtained by centrifugation, filtration and purification. Chromatin immunoprecipitation database The ESRRA Chip-seq data was obtained from Cistrome DB (http://cistrome.org/db/#/, CistromeDB: 39,355). Transcriptional binding site prediction and binding site plasmids construction The binding sites of the transcription factor ESRRA (Gene ID: 2101) and the target gene PIK3CA (Gene ID: 5290) were predicted in the JASPER 2024 database (https://jaspar.elixir.no/), in which the high-scoring MA0592.4 was selected as binding site. And the 2000 bp upstream and downstream of the transcription start sites/TSS was selected to construct a wild-type binding site plasmid, and the mutant binding site plasmid was constructed by predicting the mutation of the binding site. Dual luciferase reporter assay PCR amplification primers (Table S1) were designed according to the predicted binding site, and homologous recombination sequences were added at the 5’ end. Plasmids (wild type binding site and mutant binding site) were transferred into overexpression ESRRA cell line and vector cell line by enzymatic digestion of the dual luciferase plasmid vector, PCR amplification of target fragment, ligation of vector and target fragment, plasmid extraction and transfection. The construction and sequencing of the vector plasmid were provided by Genomeditech (Shanghai) Co., Ltd. Detection for luciferase measurement is performed according to the manufacturer’s instructions of Dual-Luciferase® Reporter Assay System (Promega, E1910). Renal function and histopathology Plasma was retained before the mice were sacrificed, centrifuged at room temperature at 3000 g for 15 min, and the supernatant was taken as serum for subsequent detection. Serum creatinine (Nanjing Jiancheng Bioengineering Institute, C011-2–1) and Blood Urea Nitrogen (Nanjing Jiancheng Bioengineering Institute, C013-2–1) were measured according to the manufacturer’s instructions. After removing the capsule, the kidney tissue was fixed with 4% paraformaldehyde, embedded inparaffin for HE and PAS staining, and then assessed under a microscope. Immunofluorescence staining The paraffin-embedded kidney tissues were cut into 4 μm–5 μm sections for immunofluorescence staining. Briefly, sections were deparaffinized, antigen retrieved, blocked (10% BSA), incubated with primary antibodies at 4°C overnight, including anti-RAB7 (1:100; Cell Signaling Technology, 9367S), anti-PLIN2 (1:100; Abcam, ab108323) and anti-LC3B (1: 100; Cell Signaling Technology, 83,506), incubated with secondary antibodies at room temperature for 1 h, and observed under Olympus laser confocal microscope (Olympus, FV3000)and take photographs. Transmission electron microscopy Fresh kidney tissue was cut into 1 mm3 pieces, fixed with 2% glutaraldehyde, dehydrated, embedded, polymerized, and stained with lead citrate by Core Facility, School of Basic Medical Sciences, Shanghai Jiao Tong University. One H-7650 transmission electron microscope (Hitachi, H-7650) was used to detect 70 nm thick sections. Immunoblotting The kidney tissues were lysed using RIPA lysis buffer (Santa Cruz Biotechnology, sc-24948), mixed with protease and phosphatase inhibitors. The total protein concentration was determined by BCA, and an equal amount of protein was loaded on a 7.5%-15% SDS-PAGE gel (Epizyme, PG111-113) and transferred to PVDF membrane (Millipore, HVLP14250). The primary antibodies were rabbit anti-ACSL4 (Abcam, ab155282), rabbit anti-GPX4 (Abcam, ab125066), rabbit anti-ESRRA (Cell Signaling Technology, 13826), mouse anti-LC3B (Cell Signaling Technology, 2775), rabbit anti-RAB7 (Cell Signaling Technology, 9367), rabbit anti-phospho-AKT (Cell Signaling Technology, 4060), rabbit anti-AKT (Cell Signaling Technology, 9272), rabbit anti-phospho-MTOR (Cell Signaling Technology, 5536), rabbit anti-MTOR (Cell Signaling Technology, 2983), rabbit anti-SQSTM1 (Proteintech, 18420–1-AP), mouse anti-ACTB/beta Actin (Proteintech, 66009–1-Ig). Blotting was performed with ECL reagent (Epizyme, SQ203). The quantification of the gray values of protein bands was dependent on ImageJ software. Cell viability analysis The viability of HK-2 cells was measured using CCK-8 kit (Dojindo, CK04) according to the manufacturer’s instructions. In brief, 10 μl of CCK-8 solution was added to HK-2 cells and incubated at 37°C for 3 h. Absorbance at 450 nm was measured every 30 min using BioTek CytationTM3. Lipid droplets and lysosome staining HK-2 cells were plated into 24-well plates on coverslips, followed by iohexol for 24 h. For monitoring LDs and lysosomes, BODIPY™ 493/503 (Thermo Fisher Scientific, D3922; 1 μM) and LysoTracker (Yeasen Biotechnology, 40739ES50; 1 μM) were added to HK-2 cells and then incubated for 30 min at 37°C and 5% CO2. Images of LDs and lysosomes were captured under an Olympus Laser Confocal Fluorescence Microscope (Olympus, Japan). Statistical analysis GraphPad Prism version 10 was used to analyze all statistical data. Quantitative data are presented as the mean ± standard error (SEM). Differences between the two groups were analyzed by the student’s t-test, and differences between multiple groups were analyzed by the one-way ANOVA test. p value was presented as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant. Supplementary Material Revised clean supplementray materials R5.docx Immunobloting original data.pdf